Design-for-Six-Sigma for Development of a Bioprocess Quality-by-Design Framework | PDA Journal of Pharmaceutical Science and Technology

References

1.↵
1. Kozlowski S.
, CDER. Biotechnology Products and Agenda Initiatives. Well Characterized Biological Products. Bethesda, MD. January, 2009.
2.↵
1. Wechsler J.
Regulatory beat: Quality standards to reshape manufacturing. Biopharm. 2004b, 20 (2).
3.↵
1. Rathore A. S.,
2. Winkle H.
Quality by design for biopharmaceuticals. Nature Biotechnology 2009, 27 (1), 26–34.
OpenUrl CrossRef PubMed Web of Science
4.↵
1. Langille S.,
2. Ensor L.,
3. Hussong D.
Quality by design for pharmaceutical microbiology. Am. Pharm. Rev. 2009, 12 (6), 80–83.
OpenUrl
5.↵
United States FDA. Pharmaceutical cGMPs for the 21^st century—a risk-based approach. September 2004. http://www.fda.gov/cder/gmp/gmp2004/gmpfinalreport2004.htm
6.↵
ICH. Q8R2 Pharmaceutical development, Step 4 version. August 2009.
7.↵
1. Woodcock J.
The concept of pharmaceutical quality. Am. Pharm. Rev. 2004, Nov/Dec.
8.↵
1. Neway J.
How to make the business case for quality by design. Biopharm Int. 2008, 21 (12), 42–47.
OpenUrl
9.↵
1. Winkle H. N.
Implemented Quality by Design. PDA/FDA Joint Regulatory Conference. Evolution of the Global Regulatory Environment: A Practical Approach to Change. Washington, DC. September 2007.
10.↵
1. Wechsler J.
FDA promotes QbD for biotech therapies. 2008. http://biopharminternational.findpharma.com/biopharm/Quality/FDA-Promotes-QbD-for-Biotech-Therapies/ArticleStandard/Article/detail/557244
11.↵
1. Neway J.
Quality by design is essential in the new US regulatory environment Next Generation Pharmaceutical 2009, 10 (emagazine) http://www.pharma.com/article/Quality-by-Design-is-Essential-in-the-New-US-Regulatory-Environment/
12.↵
1. Meyers C. A.,
2. Weigl D.
QbD and GMPs: How the convergence of science and compliance will change the way we work. Bioprocess Int. 2009, 7 (11), 22–25.
OpenUrl
13.↵
1. Lepore J.,
2. Spavins J.
PQLI design space. J. Pharm. Innov. 2008, 3, 79–87.
OpenUrl
14.↵
1. Arora T.,
2. Greene R.,
3. Mercer J.,
4. Tsang P.,
5. Casais M.,
6. Feldman S.,
7. Look J.,
8. Lubiniecki T.,
9. Mezzatesta J.,
10. Pluschkell S.,
11. Rosolowsky M.,
12. Rathore A.,
13. Schenerman M.,
14. Schofield T.,
15. Sheridan S.,
16. Smock P.,
17. Anliker S.,
18. Atkins L.,
19. McGarvey B.,
20. Meiklejohn B.,
21. Precup J.,
22. Towns J.
QbD Working Group of PhRMA Biologics and Biotechnology Leadership Committee ( Arora T., Greene R., Mercer J., Tsang P., Casais M., Feldman S., Look J., Lubiniecki T., Mezzatesta J., Pluschkell S., Rosolowsky M., Rathore A., Schenerman M., Schofield T., Sheridan S., Smock P., Anliker S., Atkins L., McGarvey B., Meiklejohn B., Precup J., Towns J.). Quality by design for biotechnology products, part 3. BioPharm Int. 2010, 23 (1), 36–45.
OpenUrl
15.↵
1. Neway J.
Practicalities for QbD. Pharmaceutical Processing 2009, 24 (2), 8–16.
OpenUrl
16.↵
1. Dwyer T.,
2. Keresty G.,
3. Sherry C.
The cost of non-conformance: the linkage between quality performance and business results. Pharmaceutical Engineering 2000, 20 (5), 8–18.
OpenUrl
17.↵
1. Ishire S. J.
1. Myers M.,
2. Keating C.,
3. Bannon J.,
4. Neblock D. S.,
5. Wojciechowski P. W.
Chapter 6. Addressing Changes Associated with Technology Transfer: A Case Study. In Current Trends in Monoclonal Antibody Development and Manufacturing; Ishire S. J., Ed.; Springer/American Association of Pharmaceutical Scientists: New York, 2010; pp 75–85.
18.↵
1. Shukla A,
2. Etzel M,
3. Gadam S
1. Wojciechowski P. W.,
2. Smit H. I.,
3. Myers M. M.,
4. Voronko P. J.,
5. Laverty T.,
6. Ramelmeier R. A.,
7. Siegel R. C.
Chapter 18. Making changes to a biopharmaceutical manufacturing process during development and commercial manufacturing: the REMICADE story. In Process scale Bioseparations for the Biopharmaceutical Industry; Shukla A, Etzel M, Gadam S, Eds.; CRC Press: Boca Raton, FL, 2007; Vol. 11, pp 507–522.
OpenUrl
19.↵
1. Torbeck L.,
2. Branning R.
QbD: convincing the skeptics. Biopharm Int. 2009, 22 (5), 52–58.
OpenUrl
20.↵
1. Mendivil S.,
2. Burns A.
Quality by design: Current regulatory status and future challenges. BioProcess Int. 2009, 7 (Suppl. 1), 84–87.
OpenUrl
21.↵
1. DiMasi J. A.,
2. Feldman L.,
3. Seckler A.,
4. Wilson A.
Trends in risks associated with new drug development: success rates for investigational drugs. Clinical Pharmacology & Therapeutics 2010, 87 (3), 272–277.
OpenUrl
22.↵
1. Rathore A. S.,
2. Saleki-Gerhardt A.,
3. Montgomery S. H.,
4. Tyler S. M.
Quality by design: industrial case studies on defining and implementing design space for pharmaceutical processes, Part 1. BioPharm Int. 2008, 21 (12), 37–41, 47.
OpenUrl
23.↵
1. Kenett R. S.,
2. Kenett D. A.
Quality by design applications in biosimilar pharmaceutical products. Accred. Qual. Assur. 2008, 13, 681–690.
OpenUrl
24.↵
1. Bohlin M.,
2. Jones H.,
3. Black S.
New developments in scale-up and QbD to ensure control over product quality. Am. Pharm. Rev. 2009, 12, 52–57.
OpenUrl
25.↵
1. Tulsi B.
Quality-by-design gets mixed reception from industry. Life Science Leader 2009, 1 (6), 32–33.
OpenUrl
26.↵
1. Julien C.,
2. Whitford W.
The biopharmaceutical industry's new operating paradigm. BioPharm. 2008, 6 (Suppl. 1), 6–14.
OpenUrl
27.↵
1. Wechsler J.
Industry, regulators move to adopt quality standards. Pharmaceutical Technology 2007, 31 (2), 30–40.
OpenUrl
28.↵
1. Shacter E.
FDA perspectives on the analytical characterization of follow-on protein products. American Chemical Society, San Francisco, March 24, 2010.
29.↵
1. Banerjee A.
Designing in quality: Approaches to defining the design space for a monoclonal antibody. Biopharm Intl. 2010, 23 (5), 26–40.
OpenUrl
30.↵
1. Shire S. J.
1. Heath C.
Chapter 5. Advancing Our Cell Culture Platform: Incorporating Lessons Learned and New Technologies. In Current trends in monoclonal antibody development and manufacturing; Shire S. J., Ed.; Springer/American Association of Pharmaceutical Scientists: New York, 2010; pp 63–72.
31.↵
1. Arora T.,
2. Greene R.,
3. Mercer J.,
4. Tsang P.,
5. Casais M.,
6. Feldman S.,
7. Look J.,
8. Lubiniecki T.,
9. Mezzatesta J.,
10. Pluschkell S.,
11. Rosolowsky M.,
12. Rathore A.,
13. Schenerman M.,
14. Schofield T.,
15. Sheridan S.,
16. Smock P.,
17. Anliker S.,
18. Atkins L.,
19. McGarvey B.,
20. Meiklejohn B.,
21. Precup J.,
22. Towns J.
QbD working group of PhRMA biologics and biotechnology leadership committee ( Arora T., Greene R., Mercer J., Tsang P., Casais M., Feldman S., Look J., Lubiniecki T., Mezzatesta J., Pluschkell S., Rosolowsky M., Rathore A., Schenerman M., Schofield T., Sheridan S., Smock P., Anliker S., Atkins L., McGarvey B., Meiklejohn B., Precup J., Towns J.). Quality by design for biotechnology products, Part 1. BioPharm Int. 2009, 22 (11), 26–36.
OpenUrl
32.↵
1. Adams M.
Design for six sigma: A potent supplement to QbD. Pharmaceutical Manufacturing 2000, 9 (2), 36–39.
OpenUrl
33.↵
1. Heilman C. J.
Coming to a biotech near you: quality by design. Part 1: its applicability in Biopharmaceuticals. BioPharm International 2008, 21 (5), 30–32.
OpenUrl
34.↵
ICH. Q9 Quality risk management, Step 4 version, January 2006.
35.↵
ICH. Q10 Pharmaceutical quality systems, April 2009.
36.↵
ICH. Q11 Development and manufacturing of drug substances (chemical entities and biotechnological/biological entities, Draft 3 version, January 2010.
37.↵
United States FDA. Process validation: General principles and practices, Guidance for Industry, January 2011.
38.↵
Parenteral Drug Association PDA Technical Report 42. Process validation of protein manufacturing. 59 (S-4), 1–28, (2005 Sep). Bethesda, MD: PDA.
39.↵
1. Avellanet J.
FDA Forecast: Nine recommendations to weather the new year. Pharmaceutical Processing 2009, 24 (1), 8–11.
OpenUrl
40.↵
1. Shanley A.
From the editor: Validating process validation. 2008. http://pharmamanufacturing.com/articles/2008/171.html
41.↵
1. Garcia T.,
2. Cook G.; ,
3. Nosal R.
PQLI key topics—Criticality, design space, and control strategy. J Pharm. Innov. 2008, 3, 60–68.
OpenUrl
42.↵
1. Weinberg S.
Taming the QbD elephant: A stochastic model. 2010. http://www.pharmaqbd.com/node/220
43.↵
1. Rathore A. S.,
2. Saleki-Gerhardt A.,
3. Montgomery S. H.,
4. Tyler S. M.
Quality by design: industrial case studies on defining and implementing design space for pharmaceutical processes, Part 2. BioPharm Int. 2009, 22 (1), 36–44.
OpenUrl
44.↵
United States FDA. PAT—A framework for innovative pharmaceutical manufacturing and quality assurance. Guidance for Industry, 2004.
45.↵
1. O'Kennedy R.
PAT for the product lifecycle of a biopharmaceutical product. Am. Pharm. Rev. 2008, 11 (1), 104–108.
OpenUrl
46.↵
1. Berridge J. C.
PQLI—What is it? Pharm. Eng. 2009, 29 (3), 36–39.
OpenUrl
47.↵
1. Hans J.,
2. Bansal A.
Biopharmaceutical information infrastructure, 2.0 (Part 1 of 2). Bioprocess Int. 2009, 7 (11), 10–19.
OpenUrl
48.↵
1. Meyers C. A.,
2. Weigl D.
Quality by design and compliance readiness. BioPharm Int. 2010, 23 (1), 22–25.
OpenUrl
49.↵
1. Coakley J.,
2. Hogan N.,
3. McGuire L.,
4. Griffin B.,
5. Casey C.,
6. Campbell C.,
7. Crean A.
A methodology for knowledge management in biopharmaceutical production. Pharm. Eng. 2010, 30 (3), 30–40.
OpenUrl
50.↵
1. Arora T.,
2. Greene R.,
3. Mercer J.,
4. Tsang P.,
5. Casais M.,
6. Feldman S.,
7. Look J.,
8. Lubiniecki T.,
9. Mezzatesta J.,
10. Pluschkell S.,
11. Rosolowsky M.,
12. Rathore A.,
13. Schenerman M.,
14. Schofield T.,
15. Sheridan S.,
16. Smock P.,
17. Anliker S.,
18. Atkins L.,
19. McGarvey B.,
20. Meiklejohn B.,
21. Precup J.,
22. Towns J.
QbD Working Group of PhRMA Biologics and Biotechnology Leadership Committee ( Arora T., Greene R., Mercer J., Tsang P., Casais M., Feldman S., Look J., Lubiniecki T., Mezzatesta J., Pluschkell S., Rosolowsky M., Rathore A., Schenerman M., Schofield T., Sheridan S., Smock P., Anliker S., Atkins L., McGarvey B., Meiklejohn B., Precup J., Towns J.). Quality by design for biotechnology products, part 2. BioPharm Int. 2009, 22 (12), 42–58.
OpenUrl
51.↵
1. Venkateshwaran T. G.,
2. Simmons S. P.,
3. Jagota N.,
4. Esherick D. G.,
5. Mann P. F.
Global regulatory submissions for QbD. Pharmaceutical Technology 2009, 33 (10), 96–102.
OpenUrl
52.↵
1. Whitford W.,
2. Julien C.
Towards better biopharmaceutical process design and control. BioPharm. 2008, 6 (Suppl. 1), 4.
OpenUrl
53.↵
1. Krause S. O.
QbD for analytical methods. BioPharm Int. 2009, 22 (2), 58.
OpenUrl
54.↵
1. Cox B.
Attention turns to business case for quality by design. The Gold Sheet, CDC Reports 2009, 43 (1), 1–9.
OpenUrl
55.↵
1. Sinclair A.,
2. Monge M.
Delivering affordable biologics from gene to vial. Bioprocess Int. 2010, 8 (3), 16–19.
OpenUrl
56.↵
1. Benevento M.,
2. Bornsztejn V.
Early validation, the difference between success and failure. Drug Discovery World 2009, 10 (3), 83–86.
OpenUrl
57.↵
1. Mire-Sluis A.,
2. Schenerman M.,
3. Mhatre R.,
4. Advant S.,
5. Dougherty J.,
6. Kozlowski S.,
7. Nashabeh W.,
8. McLeod L.
Quality by design: The next phase. BioProcess Int. 2009, 7 (1), 34–43.
OpenUrl
58.↵
1. Bush L.
Quality risk management demystified at CMC strategy forum. Biopharm Int. 2009, 22 (9), 20–26.
OpenUrl
59.↵
1. Yu L. X.,
2. Lionberger R.,
3. Olson M C.,
4. Johnston G.,
5. Buehler G.,
6. Winkle H.
Quality by design for generic drugs. Pharm. Technol. 2009, 33 (10), 122–127.
OpenUrl
60.↵
1. Rathore A. S.
Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol. 2009 27 (9), 546–553.
OpenUrl CrossRef PubMed
61.↵
1. Ende D.,
2. Bronk K. S.,
3. Mustakis J.,
4. O'Connor G.,
5. Santa Maria C. L.,
6. Nosal R.,
7. Watson T. J. N.
API quality by design example from torcetrapid manufacturing process. J. Pharm. Innov. 2007, 2 (3–4), 71–86.
OpenUrl
62.↵
1. Butler M. D.,
2. Kluck B.,
3. Bently T.
DNA spike studies for demonstrating improved clearance on chromatographic media. J. Chromatogr., A 2009, 1216, 6938–6945.
OpenUrl PubMed
63.↵
1. Scholfield T.,
2. Apostol I.,
3. Koeller G.,
4. Poers S.,
5. Stawicki M.,
6. Wolfe R. A.
A rational approach for setting and maintaining specifications for biological and biotechnology-derived products—Part 3. Biopharm. 2008, 21 (8).
64.↵
1. Hudson P. S.,
2. Baker D. D.
The post approval management plan/A tool to apply science- and risk-based approaches. Pharm. Technol. 2009, 33 (1), 82–86.
OpenUrl
65.↵
1. Montague G.,
2. Martin E.
The challenge in bioprocess development: from data to knowledge. Pharmaceutical Technology Europe 2007, 19 (9), 71–75.
OpenUrl
66.↵
1. Nosal R.,
2. Schultz T.
PQLI definition of criticality. J. Pharm. Innov. 2008, 3 (2), 69–78.
OpenUrl
67.↵
CMC biotech working group, A-Mab: A case study in bioprocess development. Version 2.1; Oct 30, 2009; http://www.ispe.org/pqli
68.↵
1. Bush L.
Determining critical quality attributes form the foundation for QbD implementation. BioPharm Int. 2008, 21 (9), 12–14.
OpenUrl
69.↵
1. Taticek R.
Implementation of QbD for large molecules: lessons learned (so far). Biomanufacturing Summit, San Diego CA, (January 28, 2009).
70.↵
1. Viornery L.,
2. Legoff P.
Implementing quality risk management. Pharm. Technol. 2009, 33 (12), 50–53.
OpenUrl
71.↵
1. MacGregor J. F.,
2. Bruwer M. J.
A framework for the development of design and control spaces. J. Pharm. Innov. 2008, 3 (1), 15–22.
OpenUrl
72.↵
1. Paul S. M.
How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery 2010, 9, 203–214.
OpenUrl CrossRef PubMed Web of Science
73.↵
1. Moreton C.
Functionality and performance of excipients in a quality-by-design world, Part 2: Excipient variability, QbD and robust formulations. Am. Pharm. Rev. 2009, 12 (2), 40–45.
OpenUrl
74.↵
1. Tsai A.
Connecting process characterization with process validation. IBC Life Sciences, Carlsbad, CA, March 2009.
75.↵
1. Rathore A. S.
Setting specifications for a biotech therapeutic product in the quality by design paradigm. BioPharm Int. 2010, 23 (1), 46–53.
OpenUrl
76.↵
1. Peterson J. J.
What your ICH Q8 design space needs: A multivariate predictive distribution. Pharmaceutical Manufacturing 2009, 8 (10), 23–28.
OpenUrl
77.↵
1. Julien C.,
2. Whitford W.
A new era for bioprocess design and control, Part 1. BioPharm 2008, 6 (Suppl. 1), 16–23.
OpenUrl

In This Issue

Print

Related Articles

Cited By...

No citing articles found.

Google Scholar

More in this TOC Section

Show more Review

Similar Articles